TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* All pregnant women with a viable singleton or multiple gestation at ≤34 weeks with gestational diabetes diagnosed in their current pregnancy requiring medical therapy. Early diagnosis GDM patients will also be included; which is defined as a diagnosis made prior to 24 weeks.~* Women with known preexisting type 2 diabetes that are in need of medical therapy.~Exclusion criteria:~* Patients \<18 years of age~* a diagnosis of GDM outside of the gestational age stated above~* known allergy/prior adverse reaction to insulin NPH or insulin detemir.~* type 1 diabetes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Levemir (Type: ACTIVE_COMPARATOR): Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
- NPH (Type: ACTIVE_COMPARATOR): Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin and Ischemia Reperfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers (18-50 years of age)~Exclusion Criteria:~* Hypercholesterolemia~* Hypertension

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Effectiveness and Safety of ULTRACET® (Tramadol Hydrochloride/Acetaminophen) Versus ULTRAM® (Tramadol Hydrochloride) Versus Placebo in Patients With Pain After Oral Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Surgical procedure involving removal of \>= 2 impacted third molars with bone removal required for at least 2 of the 3 impacted third molars~* At least moderate pain within 5 hours after oral surgery procedure~* Sufficiently alert to follow directions, communicate with study personnel and perform study procedures~* If female, using an acceptable method of birth control and has a negative urine pregnancy test~Exclusion Criteria:~* Previously treated patients who have discontinued treatment due to an adverse event~* Patients who have had inadequate pain relief from tramadol HCl/acetaminophen or tramadol~* Patients who have used pain medication (other than anesthesia) within 24 hours of receiving study medication, any long-acting over-the-counter pain medications within 3 days, or any pain medication after finishing oral surgery~* Patients with known problems with taking opioid medications or acetaminophen~* Patients with a history of abusing drugs or alcohol~* Patients with an uncontrolled medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion~* Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures~* Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected treatment area at the Day 57 visit in the following Peplin AK clinical Study: PEP005-028~Exclusion~* Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)~* Early termination from study PEP005-028

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children aged 1 to 5 years previously vaccinated with three or four doses of IPV (Group 1) or unvaccinated infants aged 6 weeks (-7 to +14 days) (Groups 2 and 3).~2. For Groups 2 and 3 (enrolled at 6 weeks of age) infants must have been vaccinated with 3 doses of bOPV and one dose of IPV prior to administration of the study vaccine, and the last Polio vaccine must have been administered at least 4 weeks prior to the study vaccine.~3. Healthy without obvious medical conditions that preclude the subject to be in the study as established by the medical history and physical examination.~4. Written informed consent obtained from 1 or 2 parent(s) or legal guardian(s) as per country regulations.~Exclusion Criteria:~1. For Group 1: polio vaccines within the 3 months prior to the administration of the study vaccine (number of previous polio vaccine doses to be documented). For Groups 2 and 3: polio vaccines prior to administration of the study vaccine other than 3 doses of bOPV and 1 dose of IPV .~2. Any confirmed or suspected immunosuppressive or known immunodeficient condition including human immunodeficiency virus (HIV) infection.~3. Family history of congenital or hereditary immunodeficiency.~4. Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).~5. Known allergy to any component of the study vaccines or to any antibiotics.~6. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections (of IPV).~7. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~8. Acute severe febrile illness at day of vaccination deemed by the Investigator to be a contraindication for vaccination (the child can be included at a later time if within age window and all in/exclusion criteria are met.).~9. Member of the subject's household (living in the same house or apartment unit) has received OPV in the last 3 months.~10. Subject who, in the opinion of the Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- SABIN monovalent OPV2 vaccine (Type: EXPERIMENTAL): SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously received and tolerated ALN-TTR02 (patisiran) in Study ALN-TTR02-002.~* Adequate Karnofsky performance status, liver function, and renal function.~Exclusion Criteria:~* Pregnant or nursing.~* Has had a liver transplant.~* Has a New York Heart Association heart failure classification \>2.~* Has unstable angina.~* Has uncontrolled clinically significant cardiac arrhythmia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ALN-TTR02 (patisiran) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with a diagnosis of EPP (confirmed by elevated free protoporphyrin in peripheral erythrocytes) of sufficient severity that they have requested treatment to alleviate their symptoms.~* Aged 18 - 70 years (inclusive)~* Written informed consent prior to the performance of any study-specific procedures.~Exclusion Criteria:~* Any allergy to afamelanotide or the polymer contained in the implant or to lignocaine or other local anaesthetic to be used during the administration of study medication.~* EPP patients with significant hepatic involvement.~* Personal history of melanoma or dysplastic nevus syndrome.~* Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions.~* Any other photodermatosis such as PLE, DLE or solar urticaria.~* Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.~* Acute history of drug or alcohol abuse (in the last 12 months).~* Patient assessed as not suitable for the study in the opinion of the Investigator (e.g. noncompliance history, allergic to local anaesthetics, faints when given injections or giving blood).~* Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating.~* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device).~* Sexually active men with partners of child bearing potential not using barrier contraception during the trial and for a period of three months thereafter.~* Participation in a clinical trial of an investigational agent within 30 days prior to the screening visit.~* Prior and concomitant therapy with medications which may interfere with the objectives of the study, including drugs that cause photosensitivity or skin pigmentation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Afamelanotide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Multiple Sclerosis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have central neuropathic pain due to multiple sclerosis (MS) based on the disease diagnostic criteria~* Adult males or females~* Have a score of 4 or greater on the daily 24-hour average pain score~* Females must test negative for pregnancy at study entry~* Complete the daily diaries for at least 70% of the days of the study~* Participants may continue other prescription and nonprescription analgesic pain medications as long as the dose has been stable for 1 month prior to study entry, and they agree to maintain that stable dose throughout the study Disease Diagnostic Criteria:~  * Diagnosis of MS at least 1 year prior to study entry~ * No MS flares or change in disease treatment for the 3 months prior to study entry~ * Daily pain due to MS for a minimum of 3 months prior to study entry~Exclusion Criteria:~* Are currently in a clinical trial of MS disease-modifying therapy~* Have pain that cannot be clearly differentiated from causes other than MS~* Any current or historical diagnosis of mania, bipolar disorder, psychosis, or schizoaffective disorder~* History of substance abuse or dependence~* Are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Duloxetine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has completed the Day 85 Visit in the original trial (Study HT-ANAM-301 or HT-ANAM-302) and is considered appropriate to continue to receive additional study drug; must start dosing on the extension study within 5 days of completing dosing on the original trial~* ECOG performance status ≤2~* Life expectancy of \>4 months at time of screening~* If woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 30 days following the last dose of study drug (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method)~* Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures~Exclusion Criteria:~* Women who are pregnant or breast-feeding~* Had major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to enrollment into the extension study; patients must be well recovered from acute effects of surgery prior to screening; patients should not have plans to undergo major surgical procedures during the treatment period~* Currently taking prescription medications intended to increase appetite or treat weight loss; these include, but are not limited to, testosterone, androgenic compounds, megestrol acetate, methylphenidate, and dronabinol~* Inability to readily swallow oral tablets; patients with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption, or obstructive symptoms) or intractable or frequent vomiting are excluded~* Has an active, uncontrolled infection~* Has known or symptomatic brain metastases~* Receiving strong CYP3A4 inhibitors~* Receiving tube feedings or parenteral nutrition (either total or partial); patients must have discontinued these treatments for at least 6 weeks prior to Day 1, and throughout the study duration~* Other clinical diagnosis, ongoing or intercurrent illness that in the Investigator's opinion would prevent the patient's participation~* Patients actively receiving a concurrent investigational agent, other than Anamorelin HCl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100 mg QD (Type: EXPERIMENTAL): 100 mg yellow coated, oval tablet; oral administration once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets identical in appearance to active tablets; oral administration once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Joined the study voluntarily and signed informed consent form;~* Age 18-75;~* ECOG 0-2;~* Esophageal squamous cell carcinoma, radical surgery ≤ 3 months, R0 resection;~* The operative incision healed well;~* T3-4N0M0, T1-4N1-3M0 (according to AJCC2009);~* No radiotherapy, chemotherapy or other treatments pre (post) surgery;~* PS ECOG 0-2;~* Life expectancy of more than 3 months;~* Hemoglobin (Hb) ≥ 9 g/dL • WBC ≥ 3 x 109/L, Neutrophils (ANC ) ≥ 1.5 x 109/L • platelet count (Pt) ≥ 100 x 109/L • Hepatic function: ALAT and ASAT \< 2.5 x ULN, TBIL\< 1.5 x ULN • Renal function: creatinine \< 1.5 x ULN~* No immuno-deficiency;~* Use of an effective contraceptive for adults to prevent pregnancy.~Exclusion Criteria:~* Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis;~* Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years;~* Participation in other interventional clinical trials within 30 days;~* Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives;~* Drug addiction, Alcoholism or AIDS;~* Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior;~* Unsuitable to be enrolled in the trial in the opinion of the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Chemo-radiation group (Type: EXPERIMENTAL): A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw\*5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does MiECC Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetes mellitus type 2~* isolated elective coronary revascularization~Exclusion Criteria:~* urgent or emergent Status~* Re-Operation~* preexisting reanimation~* preexisting renal transplantation~* chronic kidney insufficiency (GFR \< 30 ml/min)~* renal cell carcinoma~* renal artery Stenosis~* heart valve disease (middle- and high-grade)~* endocarditis~* infections (HIV, Tbc and all types of Hepatitis)~* hepatic cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MiECC (Type: ACTIVE_COMPARATOR): Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation.
- CECC (Type: ACTIVE_COMPARATOR): Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete